Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 69086420

Next Previous
X
Search
Drug Profile

JNJ 69086420

Alternative Names: 225Ac-DOTA-h11B6; JNJ-420; JNJ-6420; JNJ-69086420

Latest Information Update: 17 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Research & Development
  • Class Antibodies; Antineoplastics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 31 May 2024 Efficacy and adverse events data from a phase I trial in Prostate cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 15 Feb 2024 JNJ 69086420 is still in phase I trials for Prostate cancer in USA (NCT04644770)
  • 28 Dec 2023 No recent reports of development identified for phase-I development in Prostate-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top